Fornaro A, et al. - Researchers compared the survival of anthracycline-induced cardiomyopathy (AICM) patients with an idiopathic dilated cardiomyopathy (IDCM) patients followed at their center from 1990 to 2016. AICM was defined as onset of otherwise unexplained left ventricular ejection fraction ≤50% following anthracycline therapy. Patients with AICM or IDCM were followed with constantly optimized heart failure (HF) therapy, for 7.6 ± 5.5 and 8.1 ± 5.5 years, respectively. Relative to a matched IDCM cohort, no difference in cardiovascular mortality was observed in patients with AICM, even with cancer-related morbidity and less prevalent use of devices. Patients with AICM were recommended to be treated with appropriate guideline-directed medical therapies like other non-ischemic dilated cardiomyopathies.